When standard treatment options reach their limits, Clinical Trials (CTs) can offer a new ray of hope. This guide provides a clear roadmap for Glioblastoma Multiforme (GBM) patients and their families on how to take the first steps and what to prepare.

Step 1: Am I Eligible?

1. Confirmed Diagnosis

• A pathology report confirming a diagnosis of GBM is required.
• Most trials focus on recurrent or refractory patients (those who have relapsed after chemoradiotherapy).

2. Adequate Performance Status

• Patients should be able to perform basic activities of daily living (e.g., eating, walking).
• No severe infection or organ failure within the past month.

3. Key Documents to Prepare

• Pathology report confirming "Glioblastoma Multiforme (GBM)"
• Brain MRI scans (films or digital files) from the last 3 months
• Genetic testing reports (e.g., IDH, MGMT status)
• Complete record of prior treatment history (including drug names, doses, and schedules)

Tip: Organize your medical records in a file and keep digital copies on your phone for easy access.

Step 2: Where to Find Clinical Trials?

Three Free and Reliable Channels

1. Center for Drug Evaluation (CDE) Official Website

• Visit: National Medical Products Administration (NMPA) Center for Drug Evaluation (www.cde.org.cn)
• Navigate to: "Registration and Filing Platform" → "Clinical Trial Registration Platform"
• Search for "Glioblastoma" or "GBM"
• Click on study entries for contact information and telephone inquiries

2. Hospital Green Channels

Beijing Tiantan Hospital – Neurosurgery Clinical Trial Clinic

Shanghai Huashan Hospital – Neuro-Oncology Department

Guangzhou Sun Yat-sen Cancer Center – Comprehensive Clinical Trial Center3. Your Primary Care Physician – The Most Important Resource!

Take the initiative to tell your doctor: "I am interested in learning about clinical trial opportunities."

Physicians often have access to unpublished trial resources and emerging study opportunities.

Step 3: The Application Process

1. Pre-Screening Consultation

• The research team will explain the study objectives, treatment plan, potential risks, and expected benefits in detail.
• Be sure to request a written Informed Consent Form (ICF) and ensure you fully understand all terms before signing.

2. Comprehensive Pre-Enrollment Evaluation

• This typically includes contrast-enhanced MRI, blood tests, electrocardiogram (ECG), and review of prior treatment records.
• You may be asked to provide tumor tissue samples for molecular testing (e.g., MGMT, IDH status).

3. Treatment and Follow-Up

• Phase I CTs often require frequent hospital visits or admissions.
• Carefully document all side effects and report them promptly to the study team.

Important Note: The Informed Consent Form (ICF) is not a binding contract—you have the right to withdraw at any time without penalty. The physician must clearly explain:

• Potential risks (including unknown side effects)
• Potential benefits (including access to free novel therapies and close monitoring by expert teams)
• Your right to withdraw at any time

Screening Period: Approximately 2 weeks, including blood work, MRI, ECG, and other baseline assessments.

What Clinical Trials Offer

• Access to free cutting-edge therapies
• Close monitoring by expert teams at top-tier hospitals
• The opportunity to contribute to medical progress

"I am not a lab rat—I am a pioneer carrying a new torch of hope." — Words from a trial participant. Whether or not you choose to participate in a CT, every effort you make in the fight for life is worthy of recognition.

Hope is the light that shines through the cracks in life.

The Future is Within Reach: Beijing Tiantan Hospital is currently conducting a Phase I CT of "Survivin-Targeting DC Cell Injection" for GBM (Clinical Trial Registration No.: CTR20240438). For inquiries, please contact: 15810449839, Manager Zhang.

About the Survivin-Targeting mRNA-DC Tumor Vaccine

On January 10, 2023, tricision's mRNA-DC vaccine for GBM—Survivin-Targeting DC Cell Injection—received Clinical Trial Permission (CTP) from the National Medical Products Administration (NMPA) (Approval No. 2023LP00065), making it the world's first Survivin-targeting mRNA-DC therapeutic cancer vaccine to enter clinical trials.

The therapy involves extracting a patient's own Dendritic Cells (DCs), loading them with Messenger RNA (mRNA) encoding the Survivin antigen, and reinfusing them to induce antigen-specific CD4+ and CD8+ T cell responses. This approach is designed to eliminate residual tumor cells post-surgery, prevent recurrence, and extend survival in primary GBM patients.

Published data confirm the vaccine's efficacy: for glioma patients, median Overall Survival (OS) was 19 months in the treatment group (n=5) versus 11 months in the control group (n=28). For Small Cell Lung Cancer (SCLC) patients with brain metastases, the respective figures were 17 months (n=5) versus 7 months (n=13). One patient has been reported to have an OS exceeding 60 months (5 years), with no Dose-Limiting Toxicity (DLT) or treatment-related Adverse Events (AEs) observed across the entire cohort.